Share on StockTwits

Idenix Pharmaceuticals (NASDAQ:IDIX) was upgraded by stock analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a report issued on Monday.

Shares of Idenix Pharmaceuticals (NASDAQ:IDIX) traded up 232.37% during mid-day trading on Monday, hitting $24.03. 17,562,002 shares of the company’s stock traded hands. Idenix Pharmaceuticals has a 52 week low of $2.93 and a 52 week high of $9.32. The stock’s 50-day moving average is $5.89 and its 200-day moving average is $6.22. The company’s market cap is $3.625 billion.

Idenix Pharmaceuticals (NASDAQ:IDIX) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.19) by $0.05. Analysts expect that Idenix Pharmaceuticals will post $-0.89 EPS for the current fiscal year.

Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.